TCOYD

TCOYD Guided by the belief that every person with diabetes has the right to live a healthy, happy, and pro

Guided by the belief that every person with diabetes has the right to live a healthy, happy, and productive life, Taking Control of Your Diabetes educates and motivates people with diabetes to take a more active role in their condition.

*We love sharing the latest and greatest in diabetes education, but we are not your doctors! All of the information on our website, in our videos, on our podcasts

, on our social media platforms, and in any other current or future communication method is for the purposes of general education only. Always consult with your medical team for testing, diagnosis, treatment, and medical advice before making any changes to your healthcare. AND if you think you are having a medical emergency, call 911.*

06/24/2026

What do inhaled insulin, next-generation CGMs, ma*****na research, and smart underwear have in common?

They're all featured in the latest episode of Newsy News, where Drs. Steve Edelman and Jeremy Pettus break down some of the biggest diabetes headlines making news right now.

This episode covers the FDA approval of Afrezza for children and teens living with type 1 diabetes, including the INHALE-1 study results that helped support the approval. The discussion also explores what makes inhaled insulin different from traditional mealtime insulin and why having more treatment options is exciting for the future of diabetes care.

The conversation then shifts to Dexcom's preview of the upcoming G8 CGM, a next-generation sensor platform designed to be smaller and smarter while improving the user experience. Steve and Jeremy also discuss where diabetes technology may be headed next and what future sensors could potentially measure beyond glucose.

You'll also hear about changes to ma*****na regulations that may expand opportunities for diabetes research, including ongoing studies examining how ma*****na may affect metabolism and glucose management. And because this is Newsy News, the episode wraps up with one of the most unusual health innovations we've seen yet: wearable technology designed to monitor gut health in a very unique way.

As always, the goal is to help you stay up to date on the latest developments in diabetes care, research, and technology—with a few laughs along the way.
Which story caught your attention the most: inhaled insulin, the future of CGMs, ma*****na research, or smart underwear?

👉 Watch the full episode through here: https://bit.ly/4xHMkh9

06/23/2026

Could a new mealtime insulin option make life a little easier for kids and teens living with type 1 diabetes?

Big news! Afrezza recently received FDA approval for pediatric use, giving children and teens living with type 1 diabetes another option for mealtime insulin. The approval was based on results from the INHALE-1 study, which showed that inhaled insulin provided glucose control comparable to traditional rapid-acting injectable insulin while maintaining a reassuring safety profile.

One of the unique aspects of inhaled insulin is how quickly it starts working and leaves the body. This may help address post-meal glucose spikes while offering greater flexibility around meals, snacks, sports, and the unpredictable schedules that are often part of childhood and adolescence.

This approval is another reminder of how far diabetes care has come. As new therapies continue to emerge, families have access to an expanding toolkit of options that can help make diabetes management more flexible, personalized, and effective for the next generation.

What do you think about inhaled insulin becoming an option for kids and teens living with type 1 diabetes?

👉 Watch the full episode through here: https://bit.ly/4xHMkh9
Supported by an unrestricted educational grant from Mannkind Corporation

06/22/2026

What did the INHALE-1 study reveal about inhaled insulin for kids and teens living with type 1 diabetes?

On this episode of the TCOYD Podcast, Drs. Steve Edelman and Jeremy Pettus join pediatric endocrinologist and INHALE-1 investigator Dr. Jamie Wood to take a closer look at the study results and what they could mean for pediatric diabetes care.

The conversation explores the key findings from the INHALE-1 trial, from efficacy and safety outcomes to the real-world experiences of children, teens, and families who participated. Dr. Wood discusses how these results helped support the FDA approval of Afrezza for pediatric use and what healthcare professionals should know when considering inhaled insulin for appropriate patients.

The discussion also highlights an important real-world finding: many participants appreciated how quickly and easily inhaled insulin could be administered, offering a mealtime option that may better fit into the busy lives of kids and teens living with type 1 diabetes and their families.

How could the INHALE-1 study findings influence the way you think about mealtime insulin options for your pediatric patients living with type 1 diabetes?

🎧 Listen to the full podcast or watch on our YouTube channel here: https://bit.ly/4aUsMfA

Supported by an unrestricted educational grant from Mannkind Corporation

06/20/2026

What's happening in the world of diabetes this week? We've got you covered!

In the latest edition of Newsy News, Drs. Steve Edelman and Jeremy Pettus break down some of the biggest stories making headlines in diabetes. From the FDA approval of Afrezza for kids and teens with type 1 diabetes to exciting updates on the next generation of CGM technology, there's plenty to be excited about. Plus, they're diving into emerging research on certain plant-based compounds and their potential metabolic effects in people with diabetes.

And because it's Newsy News, the conversation doesn't stop there. Steve and Jeremy also explore fascinating gut health research, discuss what it could mean for the diabetes community, and even reveal that they now have their very own Pokémon cards. You won't want to miss that one!

At TCOYD, we know it can be hard to keep up with everything happening in the diabetes world. That's why we're here to bring you the latest updates, break down what they mean, and hopefully make you smile while we're at it.

Which diabetes news story caught your attention the most?

👉 Watch the full episode here: https://bit.ly/4gsZ7hb

06/19/2026

Could another mealtime insulin option help improve both clinical outcomes and treatment satisfaction for your pediatric patients living with type 1 diabetes?

On this episode of the TCOYD Podcast, Drs. Steve Edelman and Jeremy Pettus join pediatric endocrinologist and INHALE-1 investigator Dr. Jamie Wood to take a closer look at the INHALE-1 study and the factors that matter most when evaluating a new diabetes therapy for kids and teens.

Beyond A1C, the study examined CGM metrics, hypoglycemia, DKA, BMI, pulmonary function, and treatment satisfaction to better understand how inhaled insulin could fit into the lives of young people living with type 1 diabetes. The conversation also highlights the importance of patient- and parent-reported experiences, recognizing that confidence and satisfaction with diabetes management can be just as meaningful as clinical outcomes.

Dr. Woods, Dr. Edelman, and Dr. Pettus also discuss the importance of increasing awareness of inhaled insulin among both healthcare professionals and families, ensuring that appropriate patients have access to another FDA-approved option for individualized diabetes care.

Could treatment satisfaction play a bigger role in how we think about diabetes therapies for our pediatric patients living with type 1 diabetes?

🎧 Listen to the full podcast or watch on our YouTube channel here: https://bit.ly/4aUsMfA

Supported by an unrestricted educational grant from Mannkind Corporation

Could recognizing DKA earlier help prevent a medical emergency?Diabetic ketoacidosis (DKA) is often thought of as a comp...
06/18/2026

Could recognizing DKA earlier help prevent a medical emergency?

Diabetic ketoacidosis (DKA) is often thought of as a complication that only affects people with type 1 diabetes or those who have missed insulin doses, but it can develop in people living with either type 1 or type 2 diabetes and may be triggered by a variety of situations, including illness, changes in insulin needs, and certain medications.

One form that has received increasing attention is euglycemic DKA, which can occur in people taking SGLT2 inhibitors. Because blood sugar levels may not be as elevated as many people expect, recognizing symptoms and knowing when to check ketones becomes especially important.

Understanding your personal risk factors can help you stay one step ahead. People using insulin pumps, taking SGLT2 inhibitors, experiencing frequent high blood sugars, managing sick days, or living with early-stage type 1 diabetes may benefit from being particularly aware of the signs of DKA and having a plan in place for ketone monitoring and treatment.

The good news is that DKA can often be identified and treated before it becomes severe. Knowing the warning signs, following sick-day guidelines, and checking blood ketones when appropriate can help you take action early. Blood ketone testing remains the most accurate way to detect DKA.

In this article, we break down who is at risk, what symptoms to watch for, and practical steps that can help prevent DKA before it becomes an emergency. FreeStyle Libre

What was the most helpful thing you've learned about ketones or sick-day management?

👉 Read the full article through here: https://bit.ly/4fNC94c

06/17/2026

Could inhaled insulin help address one of the biggest unmet needs in pediatric type 1 diabetes care?

One of the greatest challenges for many children and teens with type 1 diabetes isn't knowing they need mealtime insulin—it's actually taking it. On this episode of the TCOYD Podcast, Drs. Steve Edelman and Jeremy Pettus join pediatric endocrinologist and INHALE-1 investigator Dr. Jamie Woods to discuss the real-world barriers many of your pediatric patients face and where inhaled insulin may fit into clinical practice.

The conversation explores challenges like needle anxiety, injection fatigue, pump and adhesive issues, and the social pressures of dosing insulin at school or around peers. Dr. Wood also highlights how Afrezza's rapid-on, rapid-off PK/PD profile may offer more flexibility for busy school schedules, allowing appropriate patients to dose with their first bite rather than pre-bolusing well before meals.

Not every child or teen will be a candidate for inhaled insulin, but for some of your pediatric patients, another FDA-approved mealtime option could help reduce barriers to mealtime insulin use and improve quality of life for the entire family.

Could inhaled insulin help address some of the mealtime challenges your pediatric patients face?

🎧 Listen to the full podcast or watch on our YouTube channel here: https://bit.ly/4aUsMfA

Supported by an unrestricted educational grant from Mannkind Corporation

06/16/2026

Could inhaled insulin make life with type 1 diabetes a little easier for teenagers?

In this video, Phillip shares why he chose inhaled insulin over multiple daily injections during high school and how it fit into his busy life as a student and martial arts instructor.

From carrying around diabetes supplies to taking shots at school, Phillip talks about the everyday challenges many teens with type 1 diabetes know all too well. He explains how Afrezza gave him more flexibility around meals, correction doses, and physical activity while helping diabetes feel less disruptive to his day.

Phillip also shares his honest experience getting started with inhaled insulin and encourages other teens to stay open to new diabetes technologies and treatment options that may fit their lifestyle.

Every person living with type 1 diabetes is different, and having more FDA-approved options means more opportunities to find what works best for you.

Could you see inhaled insulin fitting into your life with type 1 diabetes?

👉 Watch the video through here:https://bit.ly/43qWoxm

Supported by an unrestricted educational grant from MannKind Corporation.

06/15/2026

Could inhaled insulin change the way your pediatric patients living with type 1 diabetes manage their A1C?

Afrezza is now FDA-approved for children and teens ages 6 and older, giving healthcare professionals another mealtime insulin option to consider for appropriate pediatric patients. On this episode of the TCOYD Podcast, Drs. Steve Edelman and Jeremy Pettus sit down with pediatric endocrinologist and INHALE-1 investigator Dr. Jamie Wood to discuss what this approval means for the future of pediatric type 1 diabetes care.

They break down the INHALE-1 study, how inhaled insulin was used in children and adolescents, the safety and efficacy results, and the real-world experiences of kids, teens, and parents who participated in the trial. The conversation also explores where Afrezza may fit into clinical practice and which of your patients and their families might benefit most from having another treatment option.

Whether you care for children and teens with type 1 diabetes or simply want to stay up to date on the latest advances in diabetes management, this episode offers practical insights into one of the newest developments in pediatric diabetes care.

What questions do you have about incorporating inhaled insulin into the care of your pediatric patients with type 1 diabetes?

🎧 Listen to the full podcast or watch here: https://bit.ly/4owqRnk

Supported by an unrestricted educational grant from MannKind Corporation.

06/14/2026

Could there be an insulin option that better fits the busy, unpredictable lives of kids and teenagers with type 1 diabetes?

In this video, Dr. Steve Edelman talks about why he's excited about the recent pediatric approval of Afrezza and how it may help make everyday diabetes management a little easier for some families.

The INHALE-1 study found that Afrezza provided glucose control comparable to multiple daily injections while improving quality of life and treatment satisfaction for both kids and parents. The study also showed less weight gain and demonstrated that Afrezza was safe over the course of the one-year trial.

Dr. Edelman also highlights one of Afrezza's unique features: its rapid-on, rapid-off PK/PD profile. Because it works quickly and clears the body quickly, it can be taken at mealtime or even after eating once you know how much your child will eat. It may also help reduce delayed hypoglycemia and be especially helpful for active kids and teenagers who don't always stick to a predictable schedule.

For many families, reducing the daily burden of diabetes is just as important as improving glucose management. Having another insulin option to discuss with your child's healthcare team may help you find the approach that works best for your family.

What part of diabetes management do you wish could be a little easier for your child?

👉 Watch the video through here:https://bit.ly/43qWoxm

Supported by an unrestricted educational grant from MannKind Corporation.

Address

San Diego, CA
92121

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Telephone

+18009982693

Website

Alerts

Be the first to know and let us send you an email when TCOYD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category